-
MLX 346 seeks your views on proposals for amendments to the range of medicines which can be sold, supplied or administered by registered midwives.
-
We are aware of this urgent recall and the manufacturer's recall letters with a full list of affected part numbers have been published.
-
The Commission on Human Medicines (CHM) has advised that the UK marketing authorisations (licences) for aprotinin (Trasylol) should be suspended pending the outcome of a full Europe-wide review of the balance of risks and benefits. This review is expected to take at least three months and the licences will be suspended from 7 December until further notice.
-
We have found four unlicensed Traditional Chinese medicines (TCM) herbal products reported to contain aristolochic acids on the UK market.
-
The MHRA have issued updated advice on bone cements used in vertebroplasty and kyphoplasty procedures.
-
We have published a short article which includes the development of the guidance, key areas that have changed and best practice vigilance guidance for manufacturers selling onto the UK market.
-
The first MHRA Anti-Counterfeiting Strategy has been published, setting out the MHRA's approach to combating the availability of counterfeit medicines and devices in the UK for the next three years. We have also launched a new dedicated 24-hour hotline for reporting suspected counterfeit medicines and devices.
-
We have issued three Drug Alerts directing FDC International Ltd to recall any remaining stock of: Chloramphenicol eye drops 0.5% in FDC, Almus and Ivax liveries; Hypromellose eye drops BP 0.3%; and Timolol eye drops 0.25 and 0.5% in FDC, APS, Almus and Ivax liveries.
-
The MHRA are directing FDC International Ltd to recall any remaining stock of the above products due to rough surfaces on the bottle delivery tip. The product has been distributed in the three liveries listed above.
-
We are directing FDC International Ltd to recall any remaining stock of these products due to rough surfaces on the bottle delivery tip.